The therapeutic potential of targeting the cell cycle

Bibliography

• MCGOVERN JP: Pharmacologic principles. In: Cancer Chemotherapy Handbook. Dorr RT, Hoff DDV (Eds.), Appleton & Lange, Norwalk (1994):15–34.
   Google Scholar
• NASMYTH K: Viewpoint: putting the cell cycle in order. Science (1996) 274:1643–1645.
   PubMed Web of Science ®Google Scholar
• ELLEDGE SJ: Cell cycle checkpoints: preventing an identity crisis. Science (1996) 274:1664–1672.
   PubMed Web of Science ®Google Scholar
• ••Excellent overview of checkpoint pathways.
   Google Scholar
• HARTWELL LH, WEINERT TA: Checkpoints: controls that ensure the order of cell cycle events. Science (1989) 246:629–634.
   PubMed Web of Science ®Google Scholar
• PAULOVICH AG, TOCZYSKI DP, HARTWELL LH: When checkpoints fail. Cell (1997) 88:315–321.
   PubMed Web of Science ®Google Scholar
• PARDEE, AB: A restriction point for control of normal animal cell proliferation. Proc. Natl. Acad. ScL USA (1974) 71:1286–1290.
   PubMed Web of Science ®Google Scholar
• ••The discovery of the restriction point.
   Google Scholar
• CONNELL-CROWLEY L, ELLEDGE SJ, HARPER JW: G1 cyclin-dependent kinases are sufficient to initiate DNA synthesis in quiescent human fibroblasts. Curr. Biol. (1998) 8:65–68.
   PubMed Web of Science ®Google Scholar
• MORGAN, DO: Principles of CDK regulation. Nature (1995) 374:131–134.
   PubMed Web of Science ®Google Scholar
• ••Excellent review of the mechanisms governing cdk activity.
   Google Scholar
• GOULD, KL: Cyclin-dependent protein kinases. In: Pro- tein Kinases. Woodgett JR (Ed.), Oxford University Press, Oxford, UK (1994):149–166.
   Google Scholar
• VAN DEN HEUVEL S, HARLOW E: Distinct roles for cyclin-dependent kinases in cell cycle control. Science (1993) 262:2050–2054.
   PubMed Web of Science ®Google Scholar
• NIGG EA: Cellular substrates of p34cdc2 and its com-panion cyclin-dependent kinases. Trends Cell Biol. (1993) 3:296–301.
   PubMedGoogle Scholar
• RICKERT P, SEGHEZZI W, SHANAHAN F, CHO H, LEES E: Cyclin C/CDK8 is a novel CTD kinase associated with RNA polymerase II. Oncogene (1996) 12:2631–2640.
   PubMed Web of Science ®Google Scholar
• DYNLACHT BD, MOBERG K, LEES JA, HARLOW E, ZHU L: Specific regulation of E2F family members by cyclin-dependent kinases. Mol. Cell. Biol. (1997) 17:3867–3875.
   PubMed Web of Science ®Google Scholar
• OOKATA K, HISANAGA S, SUGITA M eta].: MAP4 is the in vivo substrate for CDC2 kinase in HeLa cells: identifica-tion of an M-phase specific and a cell cycle-independent phosphorylation site in MAP4. Biochemis-try (1997) 36:15873–15883.
   Google Scholar
• LEW DJ, DULIC V, REED SI: Isolation of three novel hu-man cyclins by rescue of G1 cyclin (C1n) function in yeast. Cell (1991) 66:1197–1206.
   PubMed Web of Science ®Google Scholar
• PINES J, HUNTER T: Isolation of a human cyclin cDNA: evidence for cyclin mRNA and protein regulation in the cell cycle and for interaction with p34cdc2. Cell (1989) 58:833–846.
   PubMed Web of Science ®Google Scholar
• CLURMAN BE, SHEAFF RJ, THRESS K, GROUDINE M, ROB-ERTS JM: Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev. (1996) 10:1979–1990.
   PubMed Web of Science ®Google Scholar
• Barinaga M: A new twist to the cell cycle. Science (1995)269 :631–632.
   PubMed Web of Science ®Google Scholar
• KING RW, DESHAIES RJ, PETERS JM, KIRSCHNER MW: How proteolysis drives the cell cycle. Science (1996) 274:1652–1659.
   PubMed Web of Science ®Google Scholar
• •In depth review of the role of ubiquitination in cell cycle control.
   Google Scholar
• PAGANO M, TAM SW, THEODORAS AM, eta].: Role of the ubiquitin-proteasome pathway in regulating abun-dance of the cyclin-dependent kinase inhibitor p27. Science (1995) 269:682–685.
   Google Scholar
• PAGANO M: Cell cycle regulation by the ubiquitin path-way. Faseb J. (1997) 11:1067–1075.
   PubMed Web of Science ®Google Scholar
• MURRAY AW, KIRSCHNER MW: Cyclin synthesis drives the early embryonic cell cycle. Nature (1989) 339:275–280.
   PubMed Web of Science ®Google Scholar
• LI J, MEYER AN, DONOGHUE DJ: Nuclear localization ofcyclin B1 mediates its biological activity and is regu-lated by phosphorylation. Proc. Natl. Acad. Sci. USA (1997) 94:502–507.
   PubMed Web of Science ®Google Scholar
• NAGASAWA M, MELAMED I, KUPFER A, GELFAND EW, LU-CAS JJ: Rapid nuclear translocation and increased ac-tivity of cyclin-dependent kinase 6 after T cell activation. J. Immunol. (1997) 158:5146–5154.
   PubMed Web of Science ®Google Scholar
• DAVID-PFEUTY T, NOUVIAN-DOOGHE Y: Human cyclinB1 is targeted to the nucleus in G1 phase prior to its ac-cumulation in the cytoplasm. Oncogene (1996) 13:1447–1460.
   PubMedGoogle Scholar
• DRAETTA G, BEACH D: Activation of cdc2 protein ki-nase during mitosis in human cells: cell-cycle-dependent phosphorylation and subunit rearrange-ment. Cell (1988) 54:17–26.
   PubMed Web of Science ®Google Scholar
• DRAETTA G, ECKSTEIN J: Cdc25 protein phosphatasesin cell proliferation. Biochim. Biophys. Acta (1997) 1332: 153–163.
   Google Scholar
• NORBURY C, BLOW J, NURSE P: Regulatory phosphory-lation of the p34cdc2 protein kinase in vertebrates. Embo. J. (1991) 10:3321–3329.
   PubMed Web of Science ®Google Scholar
• DUCOMMUN B, BRAMBILLA P, FELIX MA, et al: Cdc2 phosphorylation is required for its interaction with cyclin. Embo. J. (1991) 10:3311–3319.
   PubMed Web of Science ®Google Scholar
• SERRANO M, HANNON GJ, BEACH D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (1993) 366:704–707.
   PubMed Web of Science ®Google Scholar
• XIONG Y, HANNON GJ, ZHANG H eta].: p21 is a univer-sal inhibitor of cyclin kinases. Nature (1993) 366:701–704.
   Google Scholar
• POLYAK K, LEE MH, ERDJUMENT-BROMAGE H et al.: Cloning of p27Kipl, a cyclin-dependent kinase inhibi-tor and a potential mediator of extracellular antimito-genic signals. Cell (1994) 78:59–66.
   PubMed Web of Science ®Google Scholar
• TOYOSHIMA H, HUNTER T: p27, a novel inhibitor of G1cyclin-Cdk protein kinase activity, is related to p21. Cell (1994) 78:67–74.
   PubMed Web of Science ®Google Scholar
• HARPER JW: Cyclin dependent kinase inhibitors. Can-cer Surv. (1997) 29:91–107.
   PubMedGoogle Scholar
• SHERR CJ: Cancer cell cycles. Science (1996) 274:1672–1677.
   PubMed Web of Science ®Google Scholar
• GOODRICH DW, LEE WH: Molecular characterization of the retinoblastoma susceptibility gene. Biochimica Bio-physica Acta (1993) 1155:43–61.
   PubMed Web of Science ®Google Scholar
• WEINBERG RA: The retinoblastoma protein and cell cy-cle control. Cell (1995) 81:323–330.
   PubMed Web of Science ®Google Scholar
• •Excellent overview of RB functions.
   Google Scholar
• FUNG Y-KT, MURPHREE AL, 'FANG A et al.: Structural evi-dence for the authenticity of the human retinoblas-toma gene. Science (1987) 236:1657–1661.
   Google Scholar
• FRIEND SH, BERNARDS R, ROGEL JS et al.: A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature (1986) 323:643–646.
   PubMed Web of Science ®Google Scholar
• LEE W-H, BOOKSTEIN R, HONG F et al.: Human retino-blastoma susceptibility gene: cloning, identification, and sequence. Science (1987) 235:1394–1399.
   PubMed Web of Science ®Google Scholar
• HIEBERT SW: Regions of the retinoblastoma gene prod-uct required for its interaction with the E2F transcrip-tion factor are necessary for E2 promoter repression and pRb-mediated growth suppression. Mol. Cell Biol. (1993) 13:3384–3391.
   PubMed Web of Science ®Google Scholar
• NEVINS, JR: E2F: a link between the Rb tumor suppres-sor protein and viral oncoproteins. Science (1992) 258:424–429.
   PubMed Web of Science ®Google Scholar
• MATSUSHIME H, EWEN ME, STROM DK et al.: Identifica-tion and properties of an atypical catalytic subunit (p34PSK- J3/cdk4) for mammalian D type G1 cyclins. Cell (1992) 71:323–334.
   PubMed Web of Science ®Google Scholar
• MEYERSON M, HARLOW E: Identification of G1 kinaseactivity for cdk6, a novel cyclin D partner. Mol. Cell Biol. (1994) 14:2077–2086.
   PubMed Web of Science ®Google Scholar
• EWEN ME, SLUSS HK, SHERR CJ et al.: Functional interac-tions of the retinoblastoma protein with mammalian D- type cyclins. Cell (1993) 73:487–497.
   PubMed Web of Science ®Google Scholar
• DOWDY SF, HINDS PW, LOUIE K et al.: Physical interac-tion of the retinoblastoma protein with human D cy-clins. Cell (1993) 73:499–511.
   PubMed Web of Science ®Google Scholar
• WOLFEL T, HAUER M, SCHNEIDER J et al.: A p161NK4a-insensitive CDK4 mutant targeted by cytolytic T lym-phocytes in a human melanoma. Science (1995) 269:1281–1284.
   PubMed Web of Science ®Google Scholar
• ZUO L, WEGER J, YANG Q et al.: Germline mutations inthe p161NK4a binding domain of CDK4 in familial melanoma. Nature Genet. (1996) 12:97–99.
   PubMed Web of Science ®Google Scholar
• KHATIB ZA, MATSUSHIME H, VALENTINE M et al.: Coam-plification of the CDK4 gene with MDM2 and GLI in hu-man sarcomas. Cancer Res (1993) 53:5535–5541.
   PubMed Web of Science ®Google Scholar
• DEMETRICK DJ, ZHANG H, BEACH DH: Chromosomalmapping of human CDK2, CDK4, and CDK5 cell cycle kinase genes. Cytogenet. Cell. Genet. (1994) 66:72-74. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(6)
   Google Scholar
• ARNOLD A: The cyclin Dl/PRAD1 oncogene in human neoplasia. J. Investig. Med. (1995) 43:543–549.
   PubMed Web of Science ®Google Scholar
• ARNOLD A, KIM HG, GAZ RD et al.: Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid ade-noma. J. Chn. Invest. (1989) 83:2034–2040.
   PubMed Web of Science ®Google Scholar
• TSUJIMOTO Y, YUNIS J, ONORATO-SHOWE L et al: Mo-lecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the 011;14) chro-mosome translocation. Science (1984) 224:1403–1406.
   PubMed Web of Science ®Google Scholar
• NIELSEN, NH, EMDIN, SO, CAJANDER, J, LANDBERG, G: Deregulation of cyclin E and D1 in breast cancer is as-sociated with inactivation of the retinoblastoma pro-tein. Oncogene (1997) 14:295–304.
   PubMed Web of Science ®Google Scholar
• COURJAL F, LOUASON G, SPEISER P et al.: Cyclin gene amplification and overexpression in breast and ovar-ian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int. J. Cancer (1996) 69:247–253.
   PubMed Web of Science ®Google Scholar
• BARTKOVA J, LUKAS J, STRAUSS M, BARTEK J: Cell cycle-related variation and tissue-restricted expression of human cyclin D1 protein. J. Pathol. (1994) 172:237–245.
   PubMed Web of Science ®Google Scholar
• •First study which demonstrated that cyclin D1 protein levels were elevated in a large set of primary tumours.
   Google Scholar
• BARTKOVA J, LUKAS J, MULLER H et al: Cyclin D1 pro-tein expression and function in human breast cancer. Int. J. Cancer (1994) 57:353–361.
   PubMed Web of Science ®Google Scholar
• WEINSTAT-SASLOW D, MERINO MJ, MANROW RE et al:Overexpression of cyclin D mRNA distinguishes inva-sive and in situ breast carcinomas from non-malignant lesions. Nature Med. (1995) 1:1257–1260.
   PubMed Web of Science ®Google Scholar
• •A study linking the overexpression of cyclin D1 with poor prognosis.
   Google Scholar
• HINDS PW, DOWDY SF, EATON EN, ARNOLD A, WEIN-BERG RA: Function of a human cyclin gene as an onco-gene. Proc. Natl. Acad. Sci. USA (1994) 91:709–713.
   PubMed Web of Science ®Google Scholar
• WANG TC, CARDIFF RD, ZUKERBERG L et al: Mammary hyperplasia and carcinoma in MMTV-cyclin D1 trans-genic mice. Nature (1994) 369:669–671.
   PubMed Web of Science ®Google Scholar
• CAIRNS P, MAO L, MERLO A etal.: Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science (1994) 265:415–417.
   Google Scholar
• KAMB A, GRUIS NA, WEAVER-FELDHAUS J etal.: A cell cy-cle regulator potentially involved in genesis of many tumor types. Science (1994) 264:436–440.
   Google Scholar
• XU L, SGROI D, STERNER CJ etal.: Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas. Cancer Res. (1994) 54:5262–5264.
   Google Scholar
• LIU L, LASSAM NJ, SLINGERLAND JM et al: Germlinep161NK4A mutation and protein dysfunction in a fam-ily with inherited melanoma. Oncogene (1995) 11:405–412.
   PubMed Web of Science ®Google Scholar
• HUSSUSSIAN CJ, STRUEWING JP, GOLDSTEIN AM et al:Germline p16 mutations in familial melanoma. Nature Genet. (1994) 8:15–21.
   PubMed Web of Science ®Google Scholar
• SERRANO M, LEE H, CHIN L etal.: Role of the INK4a locusin tumor suppression and cell mortality. Cell (1996) 85:27–37.
   Google Scholar
• LUKAS J, PARRY D, AAGAARD L et al: Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature (1995) 375:503–506.
   PubMed Web of Science ®Google Scholar
• ENDERS GH, KOH J, MISSERO C, RUSTGI AK, HARLOW E: p16 inhibition of transformed and primary squamous epithelial cells. Oncogene (1996) 12:1239–1245.
   PubMed Web of Science ®Google Scholar
• NIELSEN NH, ARNERLOV C, EMDIN SO, LANDBERG G: Cy-din E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen re-ceptor status. Br. J. Cancer (1996) 74:874–880.
   PubMed Web of Science ®Google Scholar
• KITAHARA K, YASUI W, KUNIYASU H et al: Concurrent amplification of cyclin E and CDK2 genes in colorectal carcinomas. Int. J. Cancer (1995) 62:25–28.
   PubMed Web of Science ®Google Scholar
• AKAMA Y, YASUI W, YOKOZAKI H etal: Frequent ampli-fication of the cyclin E gene in human gastric carcino-mas. Jpn. Cancer Res. (1995) 86:617–621.
   Google Scholar
• WIMMEL A, LUCIBELLO FC, SEWING A, ADOLPH S, MUL-LER R: Inducible acceleration of G1 progression through tetracycline-regulated expression of human cyclin E. Oncogene (1994) 9:995–997.
   PubMed Web of Science ®Google Scholar
• RESNITZKY D, GOSSEN M, BUJARD H, REED SI: Accelera-tion of the Gl/S phase transition by expression of cy-clins D1 and E with an inducible system. Mol. Cell Biol. (1994) 14:1669–1679.
   PubMed Web of Science ®Google Scholar
• HATAKEYAMA M, BRILL JA, FINK GR, WEINBERG RA: Col-laboration of G1 cyclins in the functional inactivation of the retinoblastoma protein. Genes Dev. (1994) 8:1759–1771.
   PubMed Web of Science ®Google Scholar
• LUKAS J, HERZINGER T, HANSEN K et al: Cyclin E-induced S phase without activation of the pRb/E2F pathway. Genes Dev. (1997) 11:1479–1492.
   PubMed Web of Science ®Google Scholar
• BORTNER DM, ROSENBERG MP: Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol Cell. Biol. (1997) 17:453–459.
   PubMed Web of Science ®Google Scholar
• SHEAFF RJ, GROUDINE M, GORDON M, ROBERTS JM, CLURMAN BE: Cyclin E-CDK2 is a regulator of p27Kipl. Genes Dev. (1997) 11:1464–1478.
   PubMed Web of Science ®Google Scholar
• PORTER PL, MALONE KE, HEAGERTY PJ eta].: Expression of cell-cycle regulators p27Kipl and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nature Med. (1997) 3:222–225.
   Google Scholar
• TAN P, CADY B, WANNER M et al: The cell cycle inhibi-tor p27 is an independent prognostic marker in small (Tla,b) invasive breast carcinomas. Cancer Res. (1997) 57:1259–1263.
   PubMed Web of Science ®Google Scholar
• CATZAVELOS C, BHATTACHARYA N, UNG YC et al.: De-creased levels of the cell-cycle inhibitor p27Kipl pro-tein: prognostic implications in primary breast cancer. Nature Med. (1997) 3:227–230.
   PubMed Web of Science ®Google Scholar
• FREDERSDORF S, BURNS J, MILNE AM eta].: High level ex-pression of p27(kipl) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kipl) and degree of malignancy in human breast and colorectal cancers. Proc. Natl. Acad. Sci. USA (1997) 94:6380–6385.
   Google Scholar
• PIETENPOL JA, BOHLANDER SK, SATO Y et al.: Assign-ment of the human p27Kipl gene to 12p13 and its analysis in leukemias. Cancer Res. (1995) 55:1206–1210.
   PubMed Web of Science ®Google Scholar
• PONCE-CASTANEDA MV, LEE MH, LATRES E et al: p27Kipl: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res. (1995) 55:1211–1214.
   Google Scholar
• VLACH J, HENNECKE S, AMATI B: Phosphorylation-dependent degradation of the cyclin-dependent ki-nase inhibitor p27. Embo. J. (1997) 16:5334–5344.
   PubMed Web of Science ®Google Scholar
• LODA M, CUKOR B, TAM SW et al.: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorec-tal carcinomas. Nature Med. (1997) 3:231–234.
   PubMed Web of Science ®Google Scholar
• LEVINE AJ: p53, the cellular gatekeeper for growth and division. Cell (1997) 88:323–331.
   PubMed Web of Science ®Google Scholar
• •Recent review of p53 functions.
   Google Scholar
• EL-DEIRY WS, TOKINO T, VELCULESCU VE et al.: WAF1, a potential mediator of p53 tumor suppression. Cell (1993) 75:817–825.
   PubMed Web of Science ®Google Scholar
• •This study provided a direct link between p53 and the regu-lators of the cell cycle.
   Google Scholar
• DULIC V, KAUFMANN WK, WILSON SJ et al.: p53-dependent inhibition of cyclin-dependent kinase ac-tivities in human fibroblasts during radiation-induced G1 arrest. Cell (1994) 76:1013–1023.
   PubMed Web of Science ®Google Scholar
• MACLEOD KF, SHERRY N, HANNON G et al.: p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev. (1995) 9:935–944.
   PubMed Web of Science ®Google Scholar
• LI Y, JENKINS CW, NICHOLS MA, XIONG Y: Cell cycle ex-pression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene (1994) 9:2261–2268.
   PubMed Web of Science ®Google Scholar
• WALDMAN T, KINZLER KW, VOGELSTEIN B: p21 is neces-sary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. (1995) 55:5187–5190.
   PubMed Web of Science ®Google Scholar
• GUDAS J, NGUYEN H, LIT, HILL D, COWAN KH: Effects of cell cycle, wild-type p53 and DNA damage on p21C1P1/Wafl expression in human breast epithelial cells. Oncogene (1995) 11:253–261.
   PubMed Web of Science ®Google Scholar
• DENG C, ZHANG P, HARPER JW, ELLEDGE SJ, LEDER P: Mice lacking p21C1P1/WAF1 undergo normal develop-ment, but are defective in G1 checkpoint control. Cell (1995) 82:675–684.
   PubMed Web of Science ®Google Scholar
• WALDMAN T, LENGAUER C, KINZLER KW, VOGELSTEINB: Uncoupling of S phase and mitosis induced by anti-cancer agents in cells lacking p21. Nature (1996) 381:713–716.
   PubMed Web of Science ®Google Scholar
• NURSE P: Regulation of the eukaryotic cell cycle. Eur. J.Cancer (1997) 33:1002–1004.
   PubMed Web of Science ®Google Scholar
• KUDO Y, YASUI W, UE T et al. Overexpression of cyclin-dependent kinase-activating CDC25B phosphatase in human gastric carcinomas. Jpn. J. Can-cer Res. (1997) 88:947–952.
   PubMedGoogle Scholar
• GALAKTIONOV K, LEE AK, ECKSTEIN J et al.: CDC25 phosphatases as potential human oncogenes. Science (1995) 269:1575–1577.
   PubMed Web of Science ®Google Scholar
• GASPAROTTO D, MAESTRO R, PICCININ S et al.: Overex-pression of CDC25A and CDC25B in head and neck cancers. Cancer Res. (1997) 57:2366–2368.
   PubMed Web of Science ®Google Scholar
• GIBBS JB, OLIFF A: Pharmaceutical research in molecu-lar oncology. Cell (1994) 79:193–198.
   PubMed Web of Science ®Google Scholar
• ••An overview of the promise and pitfalls of mechanism baseddrug discovery.
   Google Scholar
• WORKMAN P: Cell proliferation, cell cycle and apopto-sis targets for cancer drug discovery: strategies, strengths and pitfalls. In: Apoptosis and cell cycle control in cancer. Thomas TSB, (Eds.), BIOS Scientific Publishers Ltd, Oxford, UK (1996):205–232.
   Google Scholar
• JEFFREY PD, RUSSO AA, POLYAK K et al.: Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature (1995) 376:313–320.
   PubMed Web of Science ®Google Scholar
• ••This study provides insight into the molecular mechanism ofcyclin activation.
   Google Scholar
• DE BONDT HL, ROSENBLATT J, JANCARIK J et al.: Crystal structure of cyclin-dependent kinase 2. Nature (1993) 363:595–602.
   PubMed Web of Science ®Google Scholar
• ••First structure of a cdk.
   Google Scholar
• APPELT K, BACQUET RJ, BARTLETT CA et al.: Design of enzyme inhibitors using iterative protein crystallo-graphic analysis. J. Med. Chem. (1991) 34:1925–1934.
   PubMed Web of Science ®Google Scholar
• HAJDUK PJ, DINGES J, MIKNIS GF et al.: NMR-based dis-covery of lead inhibitors that block DNA binding of the human papillomavirus E2 protein. J. Med. Chem. (1997) 40:3144–3150.
   PubMed Web of Science ®Google Scholar
• SHUKER SB, HAJDUK PJ, MEADOWS RP, FESIK SW: Dis-covering high-affinity ligands for proteins: SAR by NMR. Science (1996) 274:1531–1534.
   PubMed Web of Science ®Google Scholar
• GSCHWEND DA, GOOD AC, KUNTZ ID: Molecular dock-ing towards drug discovery. J. Mol. Recognit. (1996) 9:175–186.
   PubMed Web of Science ®Google Scholar
• RUSSO AA, JEFFREY PD, PAVLETICH NP: Structural basis of cyclin-dependent kinase activation by phosphory-lation. Nat. Struct. Biol. (1996) 3:696–700.
   PubMedGoogle Scholar
• TASSAN JP, SCHULTZ SJ, BARTEK J, NIGG EA: Cell cycle analysis of the activity, subcellular localization, and subunit composition of human CAK (CDK-activating kinase). J. Cell Biol. (1994) 127:467–478.
   PubMed Web of Science ®Google Scholar
• MAKELA TP, TASSAN JP, NIGG EA et al.: A cyclin associ-ated with the CDK-activating kinase M015. Nature (1994) 371:254–257.
   PubMed Web of Science ®Google Scholar
• GAUTIER J, SOLOMON MJ, BOOHER RN, BAZAN JF, KIRSCHNER MW: cdc25 is a specific tyrosine phos-phatase that directly activates p34cdc2. Cell (1991) 67:197–211.
   PubMed Web of Science ®Google Scholar
• GALAKTIONOV K, JESSUS C, BEACH D: Rafl interaction with Cdc25 phosphatase ties mitogenic signal © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(6) transduction to cell cycle activation. Genes Dev. (1995) 9:1046–1058.
   Google Scholar
• HOFFMANN I, DRAETTA G, KARSENTI E: Activation of the phosphatase activity of human cdc25A by a cdk2-cyclin E dependent phosphorylation at the Gl/S tran-sition. Embo. J. (1994) 13:4302–4310.
   PubMed Web of Science ®Google Scholar
• KUMAGAI A, DUNPHY WG: Purification and molecular cloning of Plxl, a Cdc25-regulatory kinase from Xenopus egg extracts. Science (1996) 273:1377–1380.
   PubMed Web of Science ®Google Scholar
• COLEMAN KG, WAUTLET BS, MORRISSEY D et al.: Identi-fication of CDK4 sequences involved in cyclin D1 and p16 binding. J. Biol. Chem. (1997) 272:18869–18874.
   PubMed Web of Science ®Google Scholar
• LUH FY, ARCHER SJ, DOMAILLE PJ et al.: Structure of the cyclin-dependent kinase inhibitor pl9Ink4d. Nature (1997) 389:999–1003.
   PubMed Web of Science ®Google Scholar
• RUSSO AA, JEFFREY PD, PATTEN AK, MASSAGUE J, PAV-LETICH NP: Crystal structure of the p27Kipl cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature (1996) 382:325–331.
   PubMed Web of Science ®Google Scholar
• •A detailed look at how a natural cdk inhibitor functions.
   Google Scholar
• YANG ZY, PERKINS ND, OHNO T, NABEL EG, NABEL GJ: The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nature Med. (1995) 1:1052–1056.
   PubMed Web of Science ®Google Scholar
• ST. CROIX B, FLORENES VA, RAK JW et al.: Impact of the cyclin-dependent kinase inhibitor p27Kip 1 on resis-tance of tumour cells to anticancer agents. Nature Med. (1996) 2:1204–1210.
   Google Scholar
• LOSIEWICZ MD, CARLSON BA, KAUR G, SAUSVILLE EA, WORLAND PJ: Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem. Biophys. Res. Com-mun. (1994) 201:589–595.
   PubMed Web of Science ®Google Scholar
• VESELY J, HAVLICEK L, STRNAD M et al: Inhibition of cyclin-dependent kinases by purine analogues. Eur. J. Biochem. (1994) 224:771–786.
   PubMedGoogle Scholar
• MEIJER L, BORGNE A, MULNER 0 et al.: Biochemical and cellular effects of roscovitine, a potent and selective in-hibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. (1997) 243:527–536.
   Google Scholar
• KITAGAWA M, OKABE T, OGINO H et al.: Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase. Onco-gene (1993) 8:2425–2432.
   Google Scholar
• BROOKS EE, GRAY NS, JOLY A et al.: CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation. J. Biol. Chem. (1997) 272:29207–29211.
   PubMed Web of Science ®Google Scholar
• OHASHI M, SUGIKAWA E, NAKANISHI N: Inhibition of p53 protein phosphorylation by 9-hydroxyellipticine: a possible anticancer mechanism. Jpn. J. Cancer Res. (1995) 86:819–827.
   PubMedGoogle Scholar
• PARK SG, CHEON JY, LEE YH et al.: A specific inhibitor of cyclin-dependent protein kinases, CDC2 and CDK2. Mol. Cells (1996) 6:679–683.
   Web of Science ®Google Scholar
• BOJANOWSKI K, NISHIO K, FUKUDA M, LARSEN AK, SAIJO N: Effect of suramin on p34cdc2 kinase in vitro and in extracts from human 1169 cells: evidence for a double mechanism of action. Biochem. Biophys. Res. Commun. (1994) 203:1574–1580.
   PubMed Web of Science ®Google Scholar
• ZIMMERMANN J, BUCHDUNGER E, FABBRO E et al.: Phenylamino-pyrimidines a new class of highly selec-tive protein kinase-inhibitors. 1st Italian-Swiss Meeting on Medicinal Chemistry. Turin, Italy (1997)39.
   Google Scholar
• MANSURI MM, MURTHI KK, PAL K, MITOTIX: Inhibitors of cyclin dependent kinases. World Intellectual Property Organization. United States (1997):W097/16447.
   Google Scholar
• KIM K, BRISTOL-MYERS SQUIBB: 2-Thio or 2-oxo fla-vopiridol analogs. World Intellectual Property Organiza-tion, United States(1997):W09742949.
   Google Scholar
• ZIMMERMANN J, CAPRARO H-G, PETERLI P, FURET P, NO-VARTIS: Purine derivatives and processes for their preparation. World Intellectual Property Organization, Switerzland (1997):W097/16452.
   Google Scholar
• KAWAKAMI K, FUTAMI H, TAKAHARA J, YAMAGUCHI K: UCN-01, 7-hydroxyl-staurosporine, inhibits kinase ac-tivity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. Bio-chem. Biophys. Res. Commun. (1996) 219:778–783.
   PubMed Web of Science ®Google Scholar
• NAIK RG, KATTIGE SL, BHAT SV: An antiinflammatory cum immunomodulatory priperidinylbenzopy-ranone from Dysoxylum binectariferum: isolation structure, and total synthesis. Tetrahedron (1988) 44:2081–2086.
   Web of Science ®Google Scholar
• NAIK RG, LAL B, RUPP RH et al, HOECHST AKTIENGE-SELLSCHAFT: 411-1-Benzopyran-4-on derivatives and pharmaceutical use. (1988):USP 5284856.
   Google Scholar
• KAUR G, STETLER-STEVENSON M, SEBERS S etal.: Growth inhibition with reversible cell cycle arrest of carci-noma cells by flavone L86-8275. J. Natl. Cancer Inst. (1992) 84:1736–1740.
   Google Scholar
• DE AZEVEDO WF, JR., MUELLER-DIECKMANN HJ, SCHULZE-GAHMEN U et al.: Structural basis for specific-ity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci. USA (1996) 93:2735–2740.
   Google Scholar
• CARLSON BA, DUBAY MM, SAUSVILLE EA, BRIZUELA L, WORLAND PJ: Flavopiridol induces G1 arrest with inhi-bition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res. (1996) 56:2973–2978.
   PubMed Web of Science ®Google Scholar
• SEDLACEK, HH, CZECH, J, NAIK, R, et al.: Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tu-mor therapy. Int. j Onco. (1996) 9:1143–1168.
   Google Scholar
• •A comprehensive review of preclinical flavopiridol data.
   Google Scholar
• BIBLE KC, KAUFMANN SH: Flavopiridol: a cytotoxic fla-vone that induces cell death in noncycling A549 hu-man lung carcinoma cells. Cancer Res. (1996) 56:4856–4861.
   PubMed Web of Science ®Google Scholar
• KONIG A, SCHWARTZ GK, MOHAMMAD RM, AL-KATIB A, GABRILOVE JL: The novel cyclin-dependent kinase in-hibitor flavopiridol down regulates Bc1-2 and induces growth arrest and apoptosis in chronic B-cell leuke-mia lines. Blood (1997) 90:4307-4312. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(6)
   Google Scholar
• PARKER BW, KAUR G, NIEVES-NEIRA W et al.: Early in-duction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood (1998) 91:458–465.
   PubMed Web of Science ®Google Scholar
• CZECH J, HOFFMANN D, NAIK R, SEDLACEK H-H: Antitu-moral activity of flavone L86-8275. Int. J. Oncol. (1995) 6:31–36.
   PubMed Web of Science ®Google Scholar
• DREES, M, DENGLER, WA, ROTH, T et al.: Flavopiridol (L86-8275): selective antitumor activity in vitro and ac-tivity in vivo for prostate carcinoma cells. Clinical Can-cer Res. (1997) 3:273–279.
   PubMed Web of Science ®Google Scholar
• EL-HAWARI M, EVANS E, PLETCHER J et al.: Bioavailabil-ity and preclinical toxicology of orally administered flavopiridol NSC-649890 in rats. Proc. Ann. Meet. Am. As-soc. Cancer Res. (1997) 38:A4013.
   Google Scholar
• SENDEROWICZ AM, HEADLEE D, STINSON S et al.: A phase I trial of flavopiridol (FLA), a novel cyclin-dependent kinase inhibitor, in patients with refrac-tory neoplasms. Proc. Am. Soc. Clin. Oncol. (1997) 16:226a.
   Google Scholar
• SAUSVILLE EA: Flavopiridol and UCN-01: cell cycle modulators in clinical trial. In: Cell Cycle Therapeutics. Washington DC (1997).
   Google Scholar
• SCHULZE-GAHMEN U, BRANDSEN J, JONES HD et al.: Mul-tiple modes of ligand recognition: crystal structures of cyclin- dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopenteny-ladenine. Proteins (1995) 22:378–391.
   PubMed Web of Science ®Google Scholar
• HAVLICEK L, HANUS J, VESELY J et al.: Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J. Med. Chem. (1997) 40:408–412.
   PubMed Web of Science ®Google Scholar
• EAZEVEDO WF, LECLERC S, MEIJER L et al.: Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur.J. Biochem. (1997) 243:518–526.
   PubMedGoogle Scholar
• SCHUTTE B, NIELAND L, VAN ENGELAND M et al.: The ef-fect of the cyclin-dependent kinase inhibitor olomou-cine on cell cycle kinetics. Exp. Cell. Res. (1997) 236:4–15.
   Google Scholar
• ABRAHAM RT, ACQUARONE M, ANDERSEN A et al.: Cellu-lar effects of olomoucine, an inhibitor of cyclin-dependent kinases. Biol. Cell. (1995) 83:105–120.
   PubMed Web of Science ®Google Scholar
• BUQUET-FAGOT C, LALLEMAND F, MONTAGNE MN, MESTER J: Effects of olomoucine, a selective inhibitor of cyclin-dependent kinases, on cell cycle progression in human cancer cell lines. Anticancer Drugs (1997) 8:623–631.
   PubMed Web of Science ®Google Scholar
• KITAGAWA M, HIGASHI H, TAKAHASHI IS et al.: A cyclin-dependent kinase inhibitor, butyrolactone I, in-hibits phosphorylation of RB protein and cell cycle progression. Oncogene (1994) 9:2549–2557.
   PubMed Web of Science ®Google Scholar
• NISHIO K, ISHIDA T, ARIOKA H eta].: Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines. Anticancer Res. (1996) 16:3387–3395.
   Google Scholar
• WANG Q, WORLAND PJ, CLARK JL, CARLSON BA, SAUS-VILLE EA: Apoptosis in 7- hydroxystaur osp orine- treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. Cell Growth Differ. (1995) 6:927–936.
   PubMedGoogle Scholar
• MONNOT M, MAUFFRET 0, SIMON V et al: DNA-drug rec-ognition and effects on topoisomerase II- mediated cy-totoxicity. A three-mode binding model for ellipticine derivatives. J. Biol. Chem. (1991) 266:1820–1829.
   Google Scholar
• MULTON E, RIOU JF, LEFEVRE D, AHOMADEGBE JC, RIOU G: Topoisomerase II- mediated DNA cleavage activity induced by ellipticines on the human tumor cell line N417. Biochem. Pharmacol (1989) 38:2077–2086.
   PubMed Web of Science ®Google Scholar
• MITSUYA H, POPOVIC M, YARCHOAN R et al.: Suramin protection of T cells in vitro against infectivity and cy-topathic effect of HTLV-III. Science (1984) 226:172–174.
   PubMed Web of Science ®Google Scholar
• BOJANOWSKI K, LELIEVRE S, MARKOVITS J et al.: Su-ramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. Proc. Natl Acad. Sci. USA (1992) 89:3025–3029.
   PubMed Web of Science ®Google Scholar
• HANKS SK, QUINN AM, HUNTER T: The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science (1988) 241:42–52.
   PubMed Web of Science ®Google Scholar
• ISHII H, JIROUSEK MR, KOYA D et al.: Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science (1996) 272:728–731.
   PubMed Web of Science ®Google Scholar
• DE LUCA A, MACLACHLAN TK, BAGELLA L et al.: A unique domain of pRb2/p130 acts as an inhibitor of Cdk2 ki-nase activity. J. Biol. Chem. (1997) 272:20971–20974.
   PubMed Web of Science ®Google Scholar
• WEBSTER KR, COLEMAN KG, BRISTOL-MYERS SQUIBB: Peptide inhibitors of the p33cdk2 and p34cdc2 cell cy-cle regulatory kinases and human papillomavirus E7 oncoprotein. (1997):USP 5625031.
   Google Scholar
• FAHRAEUS R, PARAMIO JM, BALL KL, LAIN S, LANE DP: In-hibition of pRb phosphorylation and cell-cycle pro-gression by a 20- residue peptide derived from p16CDKN2/INK4A. Curr. Biol. (1996) 6:84–91.
   PubMed Web of Science ®Google Scholar
• BALL KL, LAIN S, FAHRAEUS R, SMYTHE C, LANE DP: Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1. Curr. Biol. (1997) 7:71–80.
   PubMed Web of Science ®Google Scholar
• HARDIE DG: Use of protein phosphatase inhibitors in intact cells. In: Protein phosphorylation a practical ap-proach. Hardie DG (Ed.), IRL Press, Oxford University Press, Oxford, UK (1993):109–119.
   Google Scholar
• RICE RL, RUSNAK JM, YOKOKAWA F et al.: A targeted li-brary of small-molecule, tyrosine, and dual-specificity phosphatase inhibitors derived from a rational core design and random side chain variation. Biochemistry (1997) 36:15965–15974.
   PubMed Web of Science ®Google Scholar
• BARATTE B, MEIJER L, GALAKTIONOV K, BEACH D: Screening for antimitotic compounds using the cdc25 tyrosine phosphatase, an activator of the mitosis-inducing p34cdc2/cyclin Bcdc13 protein kinase. Anti-cancer Res. (1992) 12:873–880.
   PubMed Web of Science ®Google Scholar
• LAZO JS, RICE RL, CUNNINGHAM A, WIPF P, UNIVERSITY OF PITTSBURG: Phosphatase inhibitors and methods of use thereof. USA (1997) :U55700821. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(6)
   Google Scholar
• SHIBATA Y, NISHIMURA S, OKUYAMA A, NAKAMURA T: p53-independent induction of apoptosis by cyclin-dependent kinase inhibition. Cell Growth Differ (1996) 7:887–891.
   PubMedGoogle Scholar
• FISHER DE: Apoptosis in cancer therapy: crossing the threshold. Cell (1994) 78:539–542.
   PubMed Web of Science ®Google Scholar
• CHIARUGI V, MAGNELLI L, CINELLI M, BASI G: Apoptosis and the cell cycle. Cell Mol. Biol Res. (1994) 40:603–612.
   PubMedGoogle Scholar
• ANDERSON P: Kinase cascades regulating entry into apoptosis. Microbic)]. Mol. Biol. Rev. (1997) 61:33–46.
   PubMed Web of Science ®Google Scholar
• YAO SL, MCKENNA KA, SHARKIS SJ, BEDI A: Require-ment of p34cdc2 kinase for apoptosis mediated by the Fas/APO-1 receptor and interleukin lbeta-converting enzyme-related proteases. Cancer Res. (1996) 56:4551–4555.
   PubMed Web of Science ®Google Scholar
• BIBLE KC, KAUFMANN SH: Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various anti-neoplastic agents: the importance of sequence of ad-ministration. Cancer Res. (1997) 57:3375–3380.
   PubMed Web of Science ®Google Scholar
• •Evidence that cell cycle inhibitors may be useful in combina-tion with known therapeutics.
   Google Scholar
• SCHWARTZ GK, FARSI K, MASLAK P, KELSEN DP, SPRIGGS D: Potentiation of apoptosis by flavopiridol in mitomycin-c-treated gastric and breast cancer cells. Clinical Cancer Res. (1997) 3:1467–1472.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ GK, ALBINO AP, SLOAN-KETTERING INSTI-TUTE FOR CANCER RESEARCH: Combinations of PKC in-hibitors and therapeutic agents for treating cancers. World Intellectual Property Organization, United States (1996):W09730174.
   Google Scholar
• ONGKEKO W, FERGUSON DJ, HARRIS AL, NORBURY C: Inactivation of Cdc2 increases the level of apoptosis induced by DNA damage. J. Cell. Sci. (1995) 108:2897–2904.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ GK: Protein kinase c: a novel target for can-cer therapy. Keystone Symposia, Breast and Prostate Can-cer. Copper Mountain, Co. (1998):27.
   Google Scholar
• HANAHAN D, FOLKMAN J: Patterns and emerging mechanisms of the angiogenic switch during tumori-genesis. Cell (1996) 86:353–364.
   PubMed Web of Science ®Google Scholar
• FIDLER IJ, ELLIS LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell (1994) 79:185–188.
   PubMed Web of Science ®Google Scholar
• ABE J, ZHOU W, TAKUVVA N et al.: A fumagillin deriva-tive angiogenesis inhibitor, AGM-1470, inhibits activa-tion of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protoonco-gene expression in vascular endothelial cells. Cancer Res. (1994) 54:3407–3412.
   PubMed Web of Science ®Google Scholar
• KOYAMA H, NISHIZAWA Y, HOSOI M et al.: The fumagil-lin analogue TNP-470 inhibits DNA synthesis of vascu-lar smooth muscle cells stimulated by platelet-derived growth factor and insulin-like growth factor-I. Possi-ble involvement of cyclin-dependent kinase 2. Circ. Res. (1996) 79:757–764.
   Google Scholar
• HONG WK, SPORN MB: Recent advances in chemopre-vention of cancer. Science (1997) 278:1073–1077.
   PubMed Web of Science ®Google Scholar
• MCBRIDE W, LANGE RA, HILLIS LD: Restenosis after suc-cessful coronary angioplasty. Pathophysiology and prevention. New Engl. J. Med. (1988) 318:1734–1737.
   PubMed Web of Science ®Google Scholar
• CHANG MW, BARR E, LU MM, BARTON K, LEIDEN JM: Adenovirus-mediated over-expression of the cy-clin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neoin-tima formation in the rat carotid artery model of bal-loon angioplasty. J. Clin. Invest. (1995) 96:2260–2268.
   PubMed Web of Science ®Google Scholar
• EVAN GI, HARRINGTON E, MCCARTHY N et al.: Inte-grated control of cell proliferation and apoptosis by oncogenes. In: Apoptosis and Cell Cycle Control In Cancer. Thomas NSB (Ed.) BIOS Scientific Publishers Ltd, Oxford, UK (1996):109–129.
   Google Scholar
• ZWIJSEN RM, WIENTJENS E, KLOMPMAKER R et al.: CDK-independent activation of estrogen receptor by cyclin Dl. Cell (1997) 88:405–415.
   PubMed Web of Science ®Google Scholar
• NEUMAN E, LADHA MH, LIN N et al.: Cyclin D1 stimula-tion of estrogen receptor transcriptional activity inde-pendent of cdk4. Mol. Cell. Biol. (1997) 17:5338–5347.
   PubMed Web of Science ®Google Scholar
• IOLASCON A, FAIENZA MF, COPPOLA B et al.: Homozy-gous deletions of cyclin-dependent kinase inhibitor genes, p16(INK4A) and p18, in childhood T cell lineage acute lymphoblastic leukemias. Leukemia (1996) 10:255–260.
   PubMed Web of Science ®Google Scholar
• FLORES JF, POLLOCK PM, WALKER GJ et al.: Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Austra-lian melanoma kindreds. Oncogene (1997) 15:2999–3005.
   PubMed Web of Science ®Google Scholar
• CALDAS C, HAHN SA, DA COSTA LT et al.: Frequent so-matic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma [pub-lished erratum appears in Nat Genet 1994 Dec;8(4):410]. Nature Genet. (1994) 8:27–32.
   Google Scholar
• SCHUTTE M, HRUBAN RH, GERADTS J et al.: Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res. (1997) 57:3126–3130.
   PubMed Web of Science ®Google Scholar
• MORI T, MIURA K, AOKI T et al.: Frequent somatic muta-tion of the MTS1/CDK4I (multiple tumor suppres-sor/cyclin-dependent kinase 4 inhibitor)gene in esophageal squamous cell carcinoma. Cancer Res. (1994) 54:3396.
   PubMed Web of Science ®Google Scholar
• HAYASHI N, SUGIMOTO Y, TSUCHIYA E, OGAWA M, NAKAMURA Y: Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK41 (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas. Biochem. Biophys. Res. Commun. (1994) 202:1426–1430.
   PubMed Web of Science ®Google Scholar
• DE VOS S, MILLER CW, TAKEUCHI S et al.: Alterations of CDKN2 (p16) in non-small cell lung cancer. Genes Chromosomes Cancer (1995) 14:164–170.
   PubMed Web of Science ®Google Scholar
• JEN J, HARPER JW, BIGNER SH et al.: Deletion of p16 and p15 genes in brain tumors. Cancer Res. (1994) 54:6353–6358.
   PubMed Web of Science ®Google Scholar
• SPRUCK CHR, GONZALEZ-ZULUETA M, SHIBATA A et al.: p16 gene in uncultured tumours. Nature (1994) 370:183–184.
   PubMed Web of Science ®Google Scholar
• GRUIS NA, WEAVER-FELDHAUS J, LIU Q et al.: Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor sup-pression. Am. J. Pathol. (1995) 146:1199–1206.
   PubMed Web of Science ®Google Scholar
• LAPOINTE J, LACHANCE Y, LABRIE Y, LABRIE C: A p18 mutant defective in CDK6 binding in human breast cancer cells. Cancer Res. (1996) 56:4586–4589.
   Google Scholar
• KEYOMARSI K, PARDEE AB: Redundant cyclin overex-pression and gene amplification in breast cancer cells. Proc. Nati Acad. ScL USA (1993) 90:1112–1116.
   PubMed Web of Science ®Google Scholar
• KALLAKURY By, SHEEHAN CE, AMBROS RA et al: The prognostic significance of p34cdc2 and cyclin D1 pro-tein expression in prostate adenocarcinoma. Cancer (1997) 80:753–763.
   PubMed Web of Science ®Google Scholar
• YASUI W, AYHAN A, KITADAI Y et al.: Increased expres-sion of p34cdc2 and its kinase activity in human gas-tric and colonic carcinomas. Int. J. Cancer (1993) 53:36–41.
   PubMed Web of Science ®Google Scholar
• WANG A, YOSHIMI N, SUZUI M et al: Different expres-sion patterns of cyclins A, D1 and E in human colorec-tal cancer. J Cancer Res. Clin. Oncol. (1996) 122:122–126.
   PubMed Web of Science ®Google Scholar
• ZHANG T, NANNEY LB, LUONGO C et al: Concurrent overexpression of cyclin D1 and cyclin-dependent ki-nase 4 (Cdk4) in intestinal adenomas from multiple in-testinal neoplasia (Min) mice and human familial adenomatous polyposis patients. Cancer Res. (1997) 57:169–175.
   PubMed Web of Science ®Google Scholar
• WANG J, CHENIVESSE X, HENGLEIN B, BRECHOT C: Hepatitis B virus integration in a cyclin A gene in a he-patocellular carcinoma. Nature (1990) 343:555–557.
   PubMed Web of Science ®Google Scholar
• WANG A, YOSHIMI N, INO N, TANAKA T, MORI H: Over-expression of cyclin B1 in human colorectal cancers. J. Cancer Res. Clin. Oncol. (1997) 123:124–127.
   PubMed Web of Science ®Google Scholar
• BETTICHER DC, HEIGHWAY J, HASLETON PS et al.: Prog- nostic significance of CCND1 (cyclinoverexpres-sion in primary resected non-small-cell lung cancer. Br. J. Cancer (1996) 73:294–300.
   PubMed Web of Science ®Google Scholar
• BETTICHER DC, WHITE GR, VONLANTHEN S et al: G1 control gene status is frequently altered in resectable non-small cell lung cancer. Int. J. Cancer (1997) 74:556–562.
   PubMed Web of Science ®Google Scholar
• CALLENDER T, EL-NAGGAR AK, LEE MS et al: PRAD-1 (CCNDI)/cyclin D1 oncogene amplification in pri-mary head and neck squamous cell carcinoma. Cancer (1994) 74:152–158.
   PubMed Web of Science ®Google Scholar
• SHINOZAK H, OZAWA S, ANDO N et al: Cyclin D1 ampli-fication as a new predictive classification for squamous-cell carcinoma of the esophagus, adding gene information. Clinical Cancer Res. (1996) 2:1155–1161.
   PubMed Web of Science ®Google Scholar
• SHIN KY, KONG G, KIM WS et al.: Overexpression of cy-din D1 correlates with early recurrence in superficial bladder cancers. Br. J. Cancer (1997) 75:1788–1792.
   PubMed Web of Science ®Google Scholar
• KEYOMARSI K, O'LEARY N, MOLNAR G et al: Cyclin E, a potential prognostic marker for breast cancer. Cancer Res. (1994) 54:380–385.
   PubMed Web of Science ®Google Scholar
• GODDEN-KENT D, TALBOT SJ, BOSHOFF C et al.: The cy-din encoded by Kaposi's sarcoma-associated herpes-virus stimulates cdk6 to phosphorylate the retinoblastoma protein and histone Hl. J. Virol. (1997) 71:4193–4198.
   PubMed Web of Science ®Google Scholar